Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
References
1. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
2. Riordan HJ, Antonini P, Murphy MF. Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications. Am Health Drug Benefits. 2011;4(5):292-302.
3. Thakore J, Mann J, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26(1):137–141.
4. Venkatasubramanian G, Chittiprol S, Neelakantachar N, et al. Insulin and insulin-like growth factor-1 abnormalities in anti psychotic-naive schizophrenia. Am J Psychiatry. 2007;164(10):1557–1560.
5. Fernandez-Egea E, Miller B, Bernardo M., et al. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res. 2008;98(1):302–306.
6. Papanastasiou E. Interventions for the metabolic syndrome in schizophrenia: a review. Ther Adv Endocrinol Metab. 2012;3(5):141-162.
7. De Hert M, Dekker J, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6):412–424.
8. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull. 2011. December 29;[Epub ahead of print].
9. Maayan L, Vakhrusheva J, Correll C. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35(7):1520–1530.
10. Barnett A, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21(4): 357–373.
11. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009; 8(1):15–22. (B)
12. Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. London; Informa Healthcare:2009.
13. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):599.
